VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
3.155
+0.025 (0.80%)
At close: Nov 7, 2024, 4:00 PM
3.110
-0.045 (-1.43%)
After-hours: Nov 7, 2024, 6:01 PM EST
Company Description
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions.
The company’s lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.
It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications.
The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020.
VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
VYNE Therapeutics Inc.
| Country | United States |
| Founded | 2003 |
| IPO Date | Jan 25, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | David Domzalski |
Contact Details
Address: 685 Route 202/206 N, Suite 301 Bridgewater, New Jersey 08807 United States | |
| Phone | 800 775 7936 |
| Website | vynetherapeutics.com |
Stock Details
| Ticker Symbol | VYNE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001566044 |
| CUSIP Number | 92941V209 |
| ISIN Number | US92941V3087 |
| Employer ID | 45-3757789 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David T. Domzalski | Chief Executive Officer, President and Director |
| Dr. Iain A. Stuart Ph.D. | Chief Scientific Officer |
| Mutya Harsch J.D. | General Counsel, Chief Legal Officer and Company Secretary |
| Tyler Zeronda | Chief Financial Officer and Treasurer |
| Dr. Subhashis Banerjee M.D. | Senior Vice President of Clinical Development |
| Dr. Darrell S. Rigel FAAD, M.D. | Consultant |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Sep 12, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 10-Q | Quarterly Report |
| Aug 14, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| Mar 14, 2024 | EFFECT | Notice of Effectiveness |
| Mar 6, 2024 | UPLOAD | Filing |
| Mar 1, 2024 | S-3 | Registration statement under Securities Act of 1933 |